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Abstract
Concomitant infection with human immunodeficiency virus (HIV) and the Leishmania para-
site is a growing public health problem, the result of the former spreading to areas where the
latter is endemic. Leishmania infection is usually asymptomatic in immunocompetent indi-
viduals, but the proportion of HIV+ individuals in contact with the parasite who remain
asymptomatic is not known. The aim of the present work was to examine the use of cytokine
release assays in the detection of asymptomatic immune responders to Leishmania among
HIV+ patients with no previous leishmaniasis or current symptomatology. Eighty two HIV+
patients (all from Fuenlabrada, Madrid, Spain, where a leishmaniasis outbreak occurred in
2009) were examined for Leishmania infantum infection using molecular and humoral
response-based methods. None returned a positive molecular or serological result for the
parasite. Thirteen subjects showed a positive lymphoproliferative response to soluble Leish-
mania antigen (SLA), although the mean CD4+ T lymphocyte counts of these patients was
below the normal range. Stimulation of peripheral blood mononuclear cells (PBMC) or
whole blood with SLA (the lymphoproliferative assay and whole blood assay respectively),
led to the production of specific cytokines and chemokines. Thus, despite being immuno-
compromised, HIV+ patients can maintain a Th1-type cellular response to Leishmania. In
addition, cytokine release assays would appear to be useful tools for detecting these individ-
uals via the identification of IFN-γ in the supernatants of SLA-stimulated PBMC, and of IFN-
γ, MIG and IL-2 in SLA-stimulated whole blood. These biomarkers appear to be 100% reli-
able for detecting asymptomatic immune responders to Leishmania among HIV+ patients.
Author summary
The proportion of patients with HIV+ who have at some time been infected with the
Leishmania parasite, but who remain asymptomatic, is unknown. It is important to be
able to identify such patients to determine the prevalence of asymptomatic leishmaniasis
in the HIV+ population, and because these persons are at increased risk of developing
symptomatic visceral leishmaniasis. In the present work, a population of HIV+ patients
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showing a cellular immune response to Leishmania infantum was identified. These sub-
jects all showed a clear Th1-type response when their PBMC or blood were stimulated in
vitro with soluble Leishmania antigen (SLA). Cytokine release assays and the detection of
IFN-γ, MIG and IL-2 (specific biomarkers for immunity to Leishmania) were found to be
useful for detecting this population of HIV+ patients. New studies with larger numbers of
patients are needed to confirm the present results.
Introduction
Leishmaniasis is a neglected, vector-borne disease associated with high morbidity, caused by
protozoan pathogens of the genus Leishmania. In visceral leishmaniasis (VL), the most serious
form of the disease (fatal if untreated), the parasite is systemically disseminated. VL is hypoen-
demic in the Mediterranean region, where the causal agent is Leishmania infantum [1].
In 2017, nearly 160,000 people were diagnosed with HIV in the WHO European Region,
marking another year of alarming new HIV numbers [2]. HIV is most prevalent in France,
Spain, Italy and the United Kingdom; Spain has the highest DALYs value attributable to HIV/
AIDS [3].
The number of reported cases of Leishmania/HIV co-infection increased rapidly during the
1990s, a consequence of the spread of the HIV pandemic, increased awareness among report-
ing institutions, and the growing geographical overlap between the two diseases [4].
Leishmania/HIV co-infection has been recognised as an emerging problem in areas
endemic for leishmaniasis [5]. In co-infected patients, the symptoms of VL may be more
severe than in immunocompetent individuals, relapse is more common, mortality higher, par-
asite loads greater, and organs not normally involved in VL may be parasitised [6]. Co-infected
patients are also potential spreaders of Leishmania, posing a huge problem for current elimina-
tion strategies [7]. Indeed, HIV infection is recognised as an emerging challenge in the control
of VL [4].
HIV infection increases the risk of developing VL between 100 and 2320 times [6, 8]. The
marked fall in the number of CD4+ T cells caused by the virus, along with the reduced produc-
tion of IFN-γ, and the lesser leishmanicidal capacity of the macrophages [9], results in the rep-
lication and uncontrolled dissemination of the parasite around the body. HIV infection is also
associated with the reactivation of latent Leishmania infection and its progression towards VL
[1]. Similarly, active Leishmania infection can increase the replication of the virus, encourag-
ing progression to full-blown acquired immunodeficiency syndrome (AIDS) [4]. In the pre-
HAART (highly active antiretroviral therapy) era, patients with HIV also infected with Leish-
mania commonly developed VL; these days, however, the efficiency of HAART allows a vari-
able proportion of such patients to remain asymptomatic [8, 10].
The variation in the ratio of patent VL cases versus asymptomatic cases in different L. dono-
vani- and L. infantum-endemic areas (from 2.4:1 in Sudan to 50:1 in Spain [11]) reflects differ-
ences in parasite virulence and host characteristics, but perhaps also in study design and the
tests used to identify asymptomatic infection. Cell immunity usually remains positive for sev-
eral years, sometimes even throughout an individual’s life [12, 13]. However, serological mark-
ers can revert to negative within 4 months of any first sample being inspected [14]. Serology is
also unsatisfactory for detecting asymptomatic Leishmania infection in endemic areas where
mean parasitaemia levels are low or intermittent [15]. No normalised or commercial tech-
niques exists for defining asymptomatic Leishmania infection. An asymptomatic subject is
usually regarded as someone from an endemic area who shows an immune response (either
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antibodies or a positive leishmanin skin test [LST]) against Leishmania, or who has parasites in
the blood, but who remains healthy [15, 16].
VL is largely diagnosed using molecular and serological techniques. However, the serologi-
cal detection of Leishmania in patients with HIV or AIDS is not very sensitive since the para-
site elicits a weak antibody response [17, 18]. Molecular diagnoses are normally reliant on
PCR, which is highly sensitive and specific for VL in co-infected patients [19] since the parasite
load is high, even in peripheral blood. However, PCR has been used in very few studies to
detect patients with HIV who are also asymptomatic but infected with Leishmania [20, 21].
The leishmanin skin test has been widely used in the field to study the prevalence of infec-
tion, but its side effects, and the suspect quality of its manufacture, have seen it banned in
some countries, including most European nations (certainly in Spain) [17]. Cytokine release
assays using whole blood or PBMC stimulated with soluble Leishmania antigen (SLA) are use-
ful for monitoring patients who have undergone solid organ transplantation following treat-
ment for VL, and for detecting asymptomatic Leishmania infection in this population [22].
They have also been found useful for establishing the efficacy of treatment for VL in patients
also infected with HIV, and for assessing the need to maintain secondary prophylaxis in such
patients [23]. Recent studies have confirmed that IFN-γ and IL-2 are good biomarkers of
asymptomatic Leishmania infection [24], but so too are the induction protein of IFN-γ (IP-10
or CXCL10), the monokine induced by IFN-γ (MIG or CXCL9), and monocyte chemotactic
protein 1 (MCP-1 or CCL2) [25, 26].
Antiretroviral treatment has been very successful in controlling HIV replication and pre-
venting the appearance of opportunistic infections in HIV+ patients [10, 27]. HAART not
only reduces viral replication but leads to an increase in the number and functionality of CD4
+ T cells and reverts the majority of immunological abnormalities. In the pre-HAART era,
patients co-infected with HIV and Leishmania commonly failed to produce immunity against
the parasite following treatment for VL [28], but these days most HAART-treated patients do
so [23]. This begs the question of whether, in Leishmania-endemic areas, there are asymptom-
atic immune responders among HIV+ individuals (as is seen in solid organ transplantation-
associated immunodepressed patients [22]). Cell immunity techniques might be used to detect
such individuals. The aims of the present work were 1) to determine whether these techniques,
along with serological and molecular tests, can be used to make such identifications, and 2) to
characterise the immune response against the parasite in such individuals.
Materials and methods
Ethics statement
This study was approved by the Hospital de Fuenlabrada (APR12–65 and APR14-64). All par-
ticipants gave their written informed consent to be included.
Study population
Blood was collected from 82 HIV+ adult patients at the Hospital de Fuenlabrada between 2015
and 2017. All lived in Fuenlabrada (Madrid, Spain), a Leishmania infantum-endemic area with
a high prevalence of infection. All subjects were undergoing antiviral treatment and had their
viral load regularly monitored. None of the subjects had shown any sign of leishmaniasis. All
blood samples were subjected to several specific Leishmania tests (humoral, cellular and
molecular). Of the subjects providing samples with negative results to all of them, 19 were ran-
domly selected as negative controls (NC) for analysis. S1 Table provides a detailed description
of the present HIV+ patients.
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Lymphocyte populations
To determine the number of circulating lymphocytes, combinations of CD4/CD8/CD3, CD3/
CD19/CD45 and CD3/CD16+CD56/CD45 antibodies, conjugated with FITC/ PE/PerCP (BD
Tritest, USA) respectively, were added to 50 μl aliquots of peripheral blood, and analysed by
flow cytometry using FlowJo v.7.6.5 software. The percentages obtained were multiplied by the
total number of lymphocytes in the haemogram to obtain absolute values for circulating lym-
phocytes. Values for healthy individuals were used as a reference.
Preparation of soluble Leishmania antigen (SLA)
L. infantum antigen was prepared from promastigote cultures in the stationary phase (JPC
strain, MCAN/ES/98/LLM-722), as previously described [29]. The parasites were first washed
with 1X phosphate-buffered saline (PBS) and centrifuged at 1000 g for 20 min at 4˚C. The
supernatant was discarded and the pellet resuspended in lysis buffer (50 mM Tris/5 mM
EDTA/HCl, pH 7). These samples were subjected to three cycles of freezing/thawing, and then
sonicated three times (40 W for 20 s) before being centrifuged again at 27,000 g for 20 min at
4˚C. The supernatants were collected, divided into aliquots, and stored at -80˚C until use. The
protein content was quantified following the Bradford method, using the Pierce BCA Protein
Assay Kit (Bio-Rad, USA).
Culturing and stimulation of peripheral blood mononuclear cells
(lymphoproliferative assay [CPA])
Blood samples (10 ml) were collected in heparinised vials from all subjects. Peripheral blood
mononuclear cells (PBMC) were separated out using a Ficoll-Hypaque gradient (Rafer, Spain),
resuspended in complete RPMI supplemented with 10% foetal bovine serum, and cultured (in
triplicate) at an initial concentration of 2x106 cells/ml in 96-well plates with either complete
RPMI (negative control), SLA (10 μg/ml) or phytohaemagglutinin-M (PHA-M) (5 μg/ml)
[22]. All cultures were kept for 6 days at 37˚C in a 5% CO2 atmosphere. The lymphoprolifera-
tive response of each subject was then determined by bromodeoxyuridine incorporation using
the Cell Proliferation Kit (GE Healthcare Life Sciences, UK), following the manufacturer’s
instructions. Results were expressed in the form of a stimulation index (absorbance of stimu-
lated cells/unstimulated cells). The culture supernatants were collected and stored at -20˚C for
later cytokine and chemokine analysis.
Stimulation of whole blood with SLA (whole blood assay [WBA])
Aliquots (500 μl) of whole blood were incubated in tubes with 10 μg/ml SLA or 5 μg/ml
PHA-M. A further tube with no SLA was used as a negative control. All tubes were incubated
at 37˚C for 24 h, as previously described [22, 24]. They were then centrifuged at 2000 g for 10
min. The supernatants were removed and kept at -20˚C for later cytokine and chemokine
analysis.
Cytokine and chemokine determination
IFN-γ, TNF-α, granzyme B, IP-10, MIG, IL-2 and IL-10 were determined in 50 μl of superna-
tant from the PBMC cultures, and in the same volume of SLA-stimulated plasma from the
WBA [25], using the CBA Human Soluble Protein Flex Set Capture Bead Kit (Becton Dickin-
son, USA), following the manufacturer’s instructions. Results were captured by flow cytometry
using Flow Cytometric Analysis Program Array software (Becton Dickinson, USA). Results
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from each cytokine and chemokine were expressed as the difference between the SLA-stimu-
lated and control plasma concentrations.
Enzyme-linked immunosorbent assay
An enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies to SLA [22].
Briefly, 96-well plates (NuncMaxisorp Immuno Plates, USA) were coated with 100 μl/well of
10 μg/ml SLA and left overnight at 4˚C. The plates were then washed three times with PBS,
0.1% Tween 20 (PBS-T), pH7.4, and blocked with 200 μl/well of PBS containing 0.1% Tween
20 and 3% BSA for 1 h at 37˚C. After washing with PBS-T, diluted blood plasma (1/200 in
PBS-T) was added (100 μl/well) and incubated for 2 h at 37˚C. The plates were then washed
with PBS-T and 100 μl/well of 1/5000-diluted HRP-conjugated anti-human Ig (Invitrogen,
USA) were added for 30 min at 37˚C. All plates were then developed with 100 μl/well of Sigma
Fast o-phenylene diamine dihydrochloride (OPD) tablets (Sigma, USA) for 20 min. The reac-
tion was stopped with 50 μl/well of 2NHCl, and absorbance measured at 492 nm.
Immunofluorescent antibody titres
Immunofluorescent antibody titre (IFAT) analyses of plasma samples were performed using
2 × 105 L. infantum promastigotes in PBS per well (MCAN/ES/98/LLM-722), as previously
described [22]. Subject plasma was assayed as two-fold serial dilutions (from 1/20 to 1/640) in
PBS to determine total IgG levels using fluorescein isothiocyanate-conjugated goat anti-
human IgG (Fluoline G) (BioMérieux, France) diluted 1/200. The threshold titre for positivity
was set at 1:80.
rK39-ICT serological test
The rK39-ICT test (Leti Laboratories, Spain) is a rapid, commercial, immunochromatographic
test for the quantitative detection of Leishmania antibodies in serum. Serum (25 μl) was added
to the test strips, along with the provided buffer solution, in 2 ml Eppendorf tubes. After 10
min at room temperature, the strips were examined for the two bands (control and specific)
indicating a positive result.
DNA extraction
DNA was extracted from 200 μl whole blood to which had been added 400 μl of NET10 (10
mM NaCl, 10 mM EDTA, 10 mM Tris HCl), 40 μl of SDS sample buffer (10%), and 2 μl of pro-
teinase K. Samples were incubated with agitation overnight at 56˚C. The DNA was isolated
using the phenol-chloroform method, precipitating in ethanol [30]. The total DNA was resus-
pended in 100 μl of sterile distilled water and quantified using a UV-V ND-100 spectropho-
tometer (NanoDrop Technology, USA).
Leishmania nested PCR
The extracted DNA was subjected to nested PCR (Ln-PCR) using primer pairs that amplify
the Leishmania small ribosomal subunit (SSUrRNA) [31], employing a GenAmp PCR System
2700 thermocycler (Applied Biosystems, USA). The first round of reactions (30 cycles, anneal-
ing temperature 60˚C) involved the use of primers R221 and R332. The amplicons were
diluted 1/40 in distilled water, and 10 μl of this dilution used in the second round of reactions,
which involved the use of primers R223 and R333 (30 cycles, annealing temperature 65˚C).
The amplicons were then visualised in 1.5% agarose gels in TAE buffer (Tris-acetate 0.04 mM,
EDTA 1 μM, pH 8) using 0.02% GelRed staining (Biotium, USA) under a MiniBis-pro
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illuminator (DNR, Bio-imaging systems, Israel). Positive results require amplicons of 358 bp
be detected.
Statistical analysis
Normality was examined using the Shapiro-Wilk test. The Mann-Whitney U test was used to
analyse differences between unpaired groups. Significance was set at P<0.05. The cut-offs for
the ELISA and cytokine/chemokine release assays were determined by calculating the area
under the receiver operating characteristic curve (AUC) and the 95% confidence intervals
(CI). Spearman correlation coefficients were calculated between CD4+ T cells and SI, IFN-γ,
IL-2 or MIG, and between SI and WBA-associated IFN-γ or IL-2. All calculations were under-
taken using GraphPad Prism v.7 software (GraphPad Software, USA).
Results
The PBMC of HIV+ patients can mount a Leishmania-specific
lymphoproliferative response
Among the present HIV+ subjects, none of whom showed any clinical manifestation of Leish-
mania infection, there was a group of 13 (15.85%) asymptomatic immune responders (ARI
subjects) with a stimulation index (SI) of�2.39 in the SLA-CPA test (Fig 1A). The median SI
of these 13 subjects was 5.11 compared to 1.02 for the non-responders (NC) (p<0.0001). The
AUC for lymphoproliferation was 1.00 (95% CI: 1.00–1.00; p<0.0001); the sensitivity and
specificity of the SLA-CPA test was therefore 100% (Fig 1B).
Following stimulation of the PBMC of all subjects with PHA-M, no significant difference
was seen between the ARI and NC groups in terms of response; both were well capable of
responding to PHA-M (S2A Table).
No Leishmania DNA was detected in any blood sample from any HIV+ patient using
molecular techniques. In addition, the IFAT and ELISA serological tests were unable to detect
Fig 1. Lymphoproliferative response of HIV+ subjects living in the VL endemic area of Fuenlabrada following stimulation of their PBMC with
SLA. A) Response to SLA by asymptomatic immune responders (ARI; n = 13), and non-responders (NC; n = 19). B) Area under the receiver operating
characteristic curve. ����p<0.0001.
https://doi.org/10.1371/journal.pntd.0007461.g001
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any asymptomatic subject infected with L. infantum (results below the cut-offs). The serum
rK39-ICT test was negative for all subjects.
CD4+ T cell numbers were below the normal range in HIV+ subjects
showing a cellular immune response to Leishmania, although these cells
remained functional
No significant differences were seen between the ARI and NC subjects in terms of the size of
their different lymphocyte populations (Table 1). Indeed, all populations were of normal size,
except for that of the CD4+ T cells, which was below the normal lower limit (527/mm3).
Four of the ARI subjects had a CD4+ T cell count of<200/mm3. However, all the ARI sub-
jects were able to mount a cellular response to L. infantum (Fig 2, and S1 Fig).
Asymptomatic immune responders to Leishmania showed increased
cytokine/chemokine concentrations in cell culture supernatants
Following the SLA stimulation of the subjects’ PBMC, the culture supernatants of the ARI sub-
jects showed significantly greater median cytokine/chemokine concentrations than did those
of the NC subjects: IFN-γ 946.2 vs. 0 pg/ml (p<0.0001), TNF-α 226.6 vs. 0 pg/ml(p<0.0001),
granzyme B 668.7 vs. 0 pg/ml (p<0.0001) (Fig 3A–3C), IP-10 1139 vs. 0 pg/ml (p<0.0001) and
Table 1. Median size (/mm3) of different lymphocyte populations in HIV+ subjects showing/not showing cell-mediated immunity to Leishmania.
Median ± SEM
CD3+ T CD8+ T CD4+ T B cells NK cells NK-T cells
ARI 1383.39 ± 155.70 916.9 ± 91.56 435.70 ± 70.53 202.42 ± 43.70 397.59 ± 78.86 85.10 ± 20.11
NC 1203.59 ± 226.10 877.35 ± 185.64 311.00 ± 56.33 131.4 ± 32.02 147.15 ± 33.87 67.92 ± 39.79
ARI: asymptomatic immune responders to Leishmania; NC: HIV+ patients with absent immune response to Leishmania; SEM: standard error of the mean.
https://doi.org/10.1371/journal.pntd.0007461.t001
Fig 2. Specific lymphoproliferative response (stimulation index) vs. number of CD4+ T cells in HIV+ patients
with cellular immune response to Leishmania (n = 13).
https://doi.org/10.1371/journal.pntd.0007461.g002
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MIG 13,062 vs. 9.13 pg/ml (p<0.0001) (Fig 3D and 3E). No IL-2 or IL-10 was detected in any
supernatant for any subject.
Table 2 shows the high sensitivity and specificity of the increased cytokines and chemokines
as markers of L. infantum cellular immune response in HIV+ persons. However, IFN-γ
showed an AUC of 1.00 (95% CI; 1.00–1.00; p<0.0001): it therefore detected 100% of ARI
subjects.
Fig 3. Production of cytokines and chemokines following the stimulation of PBMC from HIV+ patients with SLA for 6 days. ARI = asymptomatic
immune responders to Leishmania (n = 13), NC = HIV+ patients with absent immune response to Leishmania (n = 19). Concentrations (pg/ml) of A)
IFN-γ; B) TNF-α; C) granzyme B; D) IP-10; E) MIG. ����p<0.0001.
https://doi.org/10.1371/journal.pntd.0007461.g003
Table 2. Accuracy of detection of asymptomatic individuals via cytokine/chemokine analysis of supernatants from SLA-stimulated PBMC cultures.
Analytes AUC P value Cut-off Se (%) 95% CI Sp (%) 95% CI
IFN-γ 1.000 <0.0001 > 56.29 100 75.29–100 100 86.77–100
TNF-α 0.9919 <0.0001 > 50.24 92.31 63.97–99.81 100 82.35–100
Granzyme B 0.9879 <0.0001 > 533.7 84.62 54.55–98.08 100 82.35–100
IP-10 0.9028 <0.0001 > 100.9 84.62 54.55–98.08 100 32.35–100
MIG 0.9692 <0.0001 > 3607 84.62 54.55–98.08 93.33 68.05–99.83
AUC: area under the curve; Se: sensitivity; Sp: specificity.
https://doi.org/10.1371/journal.pntd.0007461.t002
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Asymptomatic immune responders to Leishmania showed increased
cytokine/chemokine concentrations in SLA-stimulated plasma from the
whole blood assay
The SLA-stimulated plasma of the ARI subjects showed significantly greater median concentra-
tions of certain cytokines and chemokines than did that of the NC subjects: IFN-γ 101.10 vs. 0 pg/
ml (p<0.0001) (Fig 4A), granzyme B 53.64 vs. 1.68 pg/ml (p = 0.0396) (Fig 4C), IP-10 2785 vs.
2.27 pg/ml (p<0.0001) (Fig 4D), MIG 583.10 vs. 5.44 pg/ml (p<0.0001) (Fig 4E), and IL-2 291.90
vs. 0 pg/ml (p<0.0001) (Fig 4F). No significant differences were detected in the median produc-
tion of TNF-α (22.61 vs. 6.93 pg/ml; p = 0.2610) (Fig 4B) or IL-10 (1.23 vs. 0.36 pg/ml; p = 0.7231).
Table 3 shows the sensitivity and specificity of the studied cytokines and chemokines as
markers of L. infantum infection. The AUC of IFN-γ, MIG and IL-2 was 1.00 (95% CI 1.00–
1.00; p<0.0001); these biomarkers therefore detect 100% of ARI subjects. The AUC for IP-10
was 0.985 (95% CI 61.52–99.79; p<0.0001), while those of TNF-α and granzyme B were more
modest at 0.619 and 0.708 respectively.
The results show that all were capable of responding to PHA-M; no significant differences
were seen between the ARI and NC groups (S2B Table).
Strong responders in the proliferative assay were also strong responders in
the whole blood assay
A positive correlation was found between SI and IFN-γ, IL-2, IP-10 and MIG (as stimulated in
the WBA) (Fig 5 and S3 Table).
Fig 4. Cytokines and chemokines in SLA-stimulated plasma from HIV+ patients showing (ARI; n = 13) and not showing (NC; n = 19) cell-mediated
immunity to Leishmania. Concentrations (pg/ml) of A) IFN-γ; B) TNF-α; C) granzyme B; D) IP-10; E) MIG; F) IL-2. �p<0.05 ����p<0.0001.
https://doi.org/10.1371/journal.pntd.0007461.g004
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Discussion
Currently, no screening is undertaken to detect asymptomatic responders to Leishmania
among persons who are HIV+, even though their risk of developing VL is relatively high.
These carriers represent a risk to the success of Leishmania control strategies [32]. Field tools
are therefore needed that can determine the real proportion of HIV+ patients that have been
exposed to Leishmania. This is the first work using cytokine release assays to identify a sub-
population of individuals who were exposed to Leishmania but in whom no clinical disease
became manifest. This study also highlights a non-invasive, non-sensitizing simple assay of
blood stimulation easily translatable to the field.
Cytokine release assays are useful for detecting asymptomatic individuals among immuno-
competent subjects in VL-endemic areas; they can also detect the same among immunosup-
pressed subjects following solid organ transplantation [22, 24]. They are also useful for
monitoring the success of treatment in HIV+ subjects [23]. From the present results, the con-
centration of IFN-γ in the supernatants of SLA-stimulated PBMC cultures appears as a major
biomarker for both purposes. The present results show that the supernatants from the ARI
subjects showed higher concentrations of IFN-γ than did those of the NC subjects, and that
this cytokine is a 100% sensitive and specific biomarker of asymptomatic immune responders
to Leishmania among persons who are HIV+.
Fig 5. Stimulation index (dotted line) vs. IFN-γ (grey area) and IL-2 (black bars) production in SLA-stimulated plasma (WBA). The x-axis shows the
individual subjects included in this study: 1–13 ARI and 14–32 NC.
https://doi.org/10.1371/journal.pntd.0007461.g005
Table 3. Accuracy of detection of asymptomatic individuals via cytokine/chemokine analysis of SLA-stimulated plasma from the whole blood assay.
Analytes AUC P value Cut-off Se (%) 95% CI Sp (%) 95% CI
IFN-γ 1.000 <0.0001 > 11.67 100 76.84–100 100 84.56–100
TNF-α 0.619 0.2564 > 17.26 50 21.09–78.9 54.55 32.21–75.61
Granzyme B 0.708 0.0475 > 20.73 66.67 34.89–90.08 86.36 65.09–97.09
IP-10 0.985 <0.0001 > 1179 91.67 61.52–99.79 95.45 77.16–99.88
MIG 1.000 <0.0001 > 299.4 100 73.54–100 100 84.56–100
IL-2 1.000 <0.0001 > 31.66 100 73.54–100 100 84.56–100
AUC: area under the curve; Se: sensitivity; Sp: specificity.
https://doi.org/10.1371/journal.pntd.0007461.t003
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The plasma IFN-γ, IL-2 and MIG concentrations following the SLA-stimulation of whole
blood also identified 100% of these individuals. Unlike that reported for asymptomatic immu-
nocompetent individuals, no differences were seen between the ARI and NC subjects with
respect to TNF-α in the plasma of SLA-stimulated whole blood. This is probably due to the
spontaneous production of TNF-α in HIV+ subjects [33, 34].
The present results show that the ARI subjects mounted a Th1-type cellular immune
response to stimulation with SLA. However, the molecular and serological tests used were
unable to detect Leishmania DNA or anti-Leishmania antibodies in peripheral blood respec-
tively, as previously described for asymptomatic immunocompetent subjects from the same
area [24, 25]. These results suggest that cellular immune tests should also be used when trying
to identify such subjects. In line with our findings, IGRA positivity (WBA with stimulation by
the antigens ESAT-6, CFP-10 and TB7.7, and quantification of IFN-γ) seems to be a better
diagnostic tool for latent tuberculosis in HIV-infected patients than the Mantoux tuberculin
skin test [35]. Further, the present HIV+ patients had CD4+ T cells numbers as low as 49/
mm3. The capability to mount a specific cell immune response has also been described for
HIV+ subjects co-infected with cytomegalus virus (with <350 CD4+ T /mm3) and Mycobacte-
rium tuberculosis (with <100/mm3) [36, 37]. What does appear to be clear, is that HAART
helps in maintaining them capable of mounting and/or maintaining a cellular immune
response that might be involved in their asymptomatic status.
This work suffers from the limitation of a small sample size. Further studies should be
performed with more subjects, and in different Leishmania-endemic areas to validate the use
of the suggested biomarkers of asymptomatic immune responders to Leishmania in HIV+
patients. It would also be interesting to monitor the present ARI subjects to see whether they
develop active VL, and how these biomarkers may change if they do. New studies are in prog-
ress to investigate these biomarkers during the asymptomatic period preceding the onset of
active VL in HIV+ infected individuals from L. donovani endemic regions in Ethiopia.
The WHO guide for managing patients with leishmaniasis in Europe, published in 2017,
recommends the use of the SLA-stimulated lymphoproliferation test, and WBA, plus subse-
quent cytokine/chemokine determinations for detecting cellular immune responses to Leish-
mania in immunocompetent patients [17]. The present work shows that these techniques are
also valid for use with HIV+ patients living in a VL-endemic area.
In conclusion, the present results highlight the need to use cell immunity techniques to
detect asymptomatic immune responders to Leishmania among HIV+ patients with no previ-
ous leishmaniasis or current symptomatology. Supernatants from SLA-stimulated PBMC cul-
tures (CPA) can be used to look for IFN-γ, while SLA-stimulated plasma (WBA) can be used
to look for IFN-γ, MIG and IL-2, all of which are biomarkers of the above condition. Combin-
ing these tests with molecular analyses could help to determine the true size of the Leishmania
epidemic affecting the endemic area of Fuenlabrada and similar places. Some laboratory tests,
including SLA-stimulated PBMC assay, may be difficult to perform under certain conditions.
In contrast, the WBA holds much promise as a test at the point-of-care level.
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